Cambrian Biopharma CEO James Peyer Named 2022 "BioTech Company CEO of the Year" By BioTech Breakthrough
Retrieved on:
Friday, November 4, 2022
People, Leadership, Company, Science, Therapy, Founder, Sutro Biopharma, Multimedia, Yissum Research Development Company of the Hebrew University, Biotechnology, Peyer, Solution, Woman, Ageing, Safety, Tornado, Quality of life, CEO, Longevity, Geroprotector, Health, Drug development, Disco, Year, Photoionization, Efficiency, Fine chemical, Pharmaceutical industry, Cambrian, Genomics
NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today announced that its CEO, James Peyer, has been selected as "BioTech Company CEO of the Year" in the second annual BioTech Breakthrough Awards, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
Key Points:
- James Peyer, Ph.D., is CEO and Founder of Cambrian Biopharma, which is bridging the gap between academic discovery and drug development, under their Distributed Development Company (or DisCo) model.
- Since 2019, Peyer's Cambrian has grown from three drugs more than a dozen therapeutics that are currently in development.
- "Thank you so much to BioTech Breakthrough for honoring me and the work of my entire team in this way.
- Congratulations to James Peyer on winning 'BioTech Company CEO of the Year' for 2022."